Back to top
more

Axsome Therapeutics (AXSM)

(Delayed Data from NSDQ)

$103.26 USD

103.26
553,810

-0.33 (-0.32%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $103.29 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 4.62% and 3.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of 18.60% and 2.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics

by Zacks Equity Research

Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics have been highlighted in this Industry Outlook article.

Zacks Equity Research

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

5 Biotech Stocks to Bet On Bright Industry Prospects

by Ekta Bagri

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.

Zacks Equity Research

Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Alkermes (ALKS) reports mixed second-quarter 2024 results. Earnings and revenues decline year over year.

Zacks Equity Research

Wall Street Analysts Predict a 49.36% Upside in Axsome (AXSM): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Axsome (AXSM) points to a 49.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe

by Zacks Equity Research

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.

Zacks Equity Research

Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe

by Zacks Equity Research

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.

Zacks Equity Research

Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe

by Zacks Equity Research

Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.

Zacks Equity Research

Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Zacks Equity Research

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.

Zacks Equity Research

Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?

by Zacks Equity Research

Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 5.95% and 6.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

TScan Therapeutics (TCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

by Zacks Equity Research

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

by Zacks Equity Research

Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.

Zacks Equity Research

Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

by Zacks Equity Research

Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.

Zacks Equity Research

Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal

by Zacks Equity Research

Data from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental narcolepsy drug reduced weekly cataplexy attacks by 83%, compared to 66% for placebo.

Zacks Equity Research

Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

by Zacks Equity Research

Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.